Back to Newsroom
Back to Newsroom

SHAREHOLDER ALERT: SRNE CEMI MYL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Thursday, 09 July 2020 07:15 PM

The Law Offices of Vincent Wong

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / July 9, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Sorrento Therapeutics, Inc. (NASDAQ:SRNE)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/sorrento-therapeutics-inc-loss-submission-form?prid=7871&wire=1
Lead Plaintiff Deadline: July 27, 2020
Class Period: May 15, 2020 - May 22, 2020

Allegations against SRNE include that: (i) the Company's initial finding of "100% inhibition" in an in vitro virus infection will not necessarily translate to to success or safety in vivo, or in person; (ii) the Company's finding was not a "cure" for COVID-19; and (ii) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Chembio Diagnostics, Inc. (NASDAQ:CEMI)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/chembio-diagnostics-inc-loss-submission-form?prid=7871&wire=1
Lead Plaintiff Deadline: August 17, 2020
Class Period: March 12, 2020 - June 16, 2020

According to the filed complaint, defendants engaged in a scheme to deceive the market and a course of conduct that artificially inflated Chembio's stock price and operated as a fraud or deceit by misrepresenting the efficacy of the Company's Dual Path Platform ("DPP") COVID-19 test. Defendants allegedly achieved this by making false statements about Chembio's DPP COVID-19 test, although they knew or at least recklessly disregarded that there were material performance concerns with the test. When defendants' prior misrepresentations were disclosed and became apparent to the market, the price of Chembio stock fell precipitously as the prior artificial inflation came out of Chembio's stock price.

Mylan N.V. (NASDAQ:MYL)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/mylan-n-v-loss-submission-form-2?prid=7871&wire=1
Lead Plaintiff Deadline: August 25, 2020
Class Period: February 16, 2016 - May 7, 2019

Allegations against MYL include that: 1) the Food and Drug Administration's investigation into the Company's manufacturing plant in Morgantown, West Virginia was the result of whistleblower allegations, and not, as Mylan insinuated, the result of a "regular" inspection; and 2) defendants knew, or were reckless in not knowing that, as a result of Mylan's continued efforts to remain uncooperative with the Food and Drug Administration, the Morgantown plant would continue to incur substantial setbacks.

To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

SOURCE: The Law Offices of Vincent Wong

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: